Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer

Cancer Biology and Therapy

Volumn 17, Issue 5, 2016, Pages 515-525

  Yang, Yong ^a   Zhang, Peng ^a   Zhao, Yanfeng ^a   Yang, Jie ^a   Jiang, Gening ^a   Fan, Jie ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin resistance; E2F1; HMGA2; miR 26a; non small cell lung cancer

Indexed keywords

CISPLATIN; HIGH MOBILITY GROUP A2 PROTEIN; MICRORNA 26A; PROTEIN BCL 2; PROTEIN KINASE B; TRANSCRIPTION FACTOR E2F1; ANTINEOPLASTIC AGENT; MICRORNA;

3' UNTRANSLATED REGION; A549 CELL LINE; ARTICLE; ASSAY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ANALYSIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; COLONY FORMATION; DOWN REGULATION; DRUG SENSITIVITY ASSAY; ECTOPIC EXPRESSION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; LUCIFERASE ASSAY; LUNG ADENOCARCINOMA; MTT ASSAY; NON SMALL CELL LUNG CANCER; PROCEDURES CONCERNING CELLS; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUNEL ASSAY; WESTERN BLOTTING; GENETIC TRANSFECTION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; HUMANS; LUNG NEOPLASMS; MICRORNAS; TRANSFECTION;

EID: 84964470765     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1095405     Document Type: Article

References (63)

1. R.Siegel, D.Naishadham, A.Jemal. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
2. P.Seve, T.Reiman, C.Dumontet. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 2010; 67:136-43; PMID:19828208; http://dx.doi.org/10.1016/j.lungcan.2009.09.007
3. Z.H.Siddik. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-79; PMID:14576837; http://dx.doi.org/10.1038/sj.onc.1206933
4. X.Xiao, S.Yu, S.Li, J.Wu, R.Ma, H.Cao, Y.Zhu, J.Feng. Exosomes: decreased sensitivity of lung cancer A549 cells to cisplatin. PloS one 2014; 9:e89534; PMID:24586853; http://dx.doi.org/10.1371/journal.pone.0089534
5. D.J.Stewart. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007; 63:12-31; PMID:17336087; http://dx.doi.org/10.1016/j.critrevonc.2007.02.001
6. D.P.Bartel. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97; PMID:14744438; http://dx.doi.org/10.1016/S0092-8674(04)00045-5
7. B.P.Lewis, C.B.Burge, D.P.Bartel. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:15-20; PMID:15652477; http://dx.doi.org/10.1016/j.cell.2004.12.035
8. A.Kozomara, S.Griffiths-Jones. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39:D152-7; PMID:21037258; http://dx.doi.org/10.1093/nar/gkq1027
9. X.Li, J.Zhang, L.Gao, S.McClellan, M.A.Finan, T.W.Butler, L.B.Owen, G.A.Piazza, Y.Xi. MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit. Cell Death Differ 2012; 19:378-86; PMID:21979467; http://dx.doi.org/10.1038/cdd.2011.127
10. J.Krutzfeldt, N.Rajewsky, R.Braich, K.G.Rajeev, T.Tuschl, M.Manoharan, M.Stoffel. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005; 438:685-9; PMID:16258535; http://dx.doi.org/10.1038/nature04303
11. J.Elmen, M.Lindow, S.Schutz, M.Lawrence, A.Petri, S.Obad, M.Lindholm, M.Hedtjärn, H.F.Hansen, U.Berger, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452:896-9; PMID:18368051; http://dx.doi.org/10.1038/nature06783
12. Y.S.Lee, A.Dutta. MicroRNAs: small but potent oncogenes or tumor suppressors. Curr Opin Investig Drugs 2006; 7:560-4; PMID:16784027
13. C.Caldas, J.D.Brenton. Sizing up miRNAs as cancer genes. Nat Med 2005; 11:712-4; PMID:16015356; http://dx.doi.org/10.1038/nm0705-712
14. M.T.van Jaarsveld, J.Helleman, A.W.Boersma, P.F.van Kuijk, W.F.van Ijcken, E.Despierre, I.Vergote, R.H.Mathijssen, E.M.Berns, J.Verweij, et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 2013; 32:4284-93; PMID:23045278; http://dx.doi.org/10.1038/onc.2012.433
15. Y.Zhang, Q.Lu, X.Cai. MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett 2013; 587:3069-75; PMID:23932924; http://dx.doi.org/10.1016/j.febslet.2013.06.058
16. L.Sun, Y.Yao, B.Liu, Z.Lin, L.Lin, M.Yang, W.Zhang, W.Chen, C.Pan, Q.Liu, et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012; 31:432-45; PMID:21725369; http://dx.doi.org/10.1038/onc.2011.263
17. Y.Yang, H.Li, S.Hou, B.Hu, J.Liu, J.Wang. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PloS One 2013; 8:e65309.
18. W.Jiang, Y.Zhang, F.Meng, B.Lian, X.Chen, X.Yu, E.Dai, S.Wang, X.Liu, X.Li, et al. Identification of active transcription factor and miRNA regulatory pathways in Alzheimer disease. Bioinformatics 2013; 29:2596-602; PMID:23990414; http://dx.doi.org/10.1093/bioinformatics/btt423
19. M.Safran, I.Solomon, O.Shmueli, M.Lapidot, S.Shen-Orr, A.Adato, U.Ben-Dor, N.Esterman, N.Rosen, I.Peter, et al. GeneCards 2002: towards a complete, object-oriented, human gene compendium. Bioinformatics 2002; 18:1542-3; PMID:12424129; http://dx.doi.org/10.1093/bioinformatics/18.11.1542
20. M.Lu, Q.Zhang, M.Deng, J.Miao, Y.Guo, W.Gao, Q.Cui. An analysis of human microRNA and disease associations. Plos One 2008; 3:e3420; PMID:18923704; http://dx.doi.org/10.1371/journal.pone.0003420
21. Q.Jiang, Y.Wang, Y.Hao, L.Juan, M.Teng, X.Zhang, M.Li, G.Wang, Y.Liu. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 2009; 37:D98-104; PMID:18927107; http://dx.doi.org/10.1093/nar/gkn714
22. M.D.Wilkerson, X.Yin, V.Walter, N.Zhao, C.R.Cabanski, M.C.Hayward, C.R.Miller, M.A.Socinski, A.M.Parsons, L.B.Thorne, et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. Plos One 2012; 7:e36530; PMID:22590557; http://dx.doi.org/10.1371/journal.pone.0036530
23. I.Amelio, M.Gostev, R.A.Knight, A.E.Willis, G.Melino, A.V.Antonov. DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. Cell Death Dis 2014; 5:e1051; PMID:24503543; http://dx.doi.org/10.1038/cddis.2014.9
24. R.C.Friedman, K.K.Farh, C.B.Burge, D.P.Bartel. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19:92-105; PMID:18955434; http://dx.doi.org/10.1101/gr.082701.108
25. M.Fedele, G.M.Pierantoni, R.Visone, A.Fusco. E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression. Cell Div 2006; 1:17; PMID:16914062; http://dx.doi.org/10.1186/1747-1028-1-17
26. M.Fedele, R.Visone, I.De Martino, G.Troncone, D.Palmieri, S.Battista, A.Ciarmiello, P.Pallante, C.Arra, R.M.Melillo, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006; 9:459-71; PMID:16766265; http://dx.doi.org/10.1016/j.ccr.2006.04.024
27. S.Tomida, T.Takeuchi, Y.Shimada, C.Arima, K.Matsuo, T.Mitsudomi, Y.Yatabe, T.Takahashi. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 2009; 27:2793-9; PMID:19414676; http://dx.doi.org/10.1200/JCO.2008.19.7053
28. M.Martini, M.C.De Santis, L.Braccini, F.Gulluni, E.Hirsch. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med 2014; 46:372-83; PMID:24897931; http://dx.doi.org/10.3109/07853890.2014.912836
29. S.Ladu, D.F.Calvisi, E.A.Conner, M.Farina, V.M.Factor, S.S.Thorgeirsson. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 2008; 135:1322-32; PMID:18722373; http://dx.doi.org/10.1053/j.gastro.2008.07.012
30. A.Belkhiri, A.A.Dar, A.Zaika, M.Kelley, W.El-Rifai. t-Darpp promotes cancer cell survival by upregulation of Bcl2 through Akt-dependent mechanism. Cancer Res 2008; 68:395-403; PMID:18199533; http://dx.doi.org/10.1158/0008-5472.CAN-07-1580
31. W.M.Gommans, E.Berezikov. Controlling miRNA regulation in disease. Methods Mol Biol 2012; 822:1-18; PMID:22144188; http://dx.doi.org/10.1007/978-1-61779-427-8_1
32. B.Bao, S.Ali, S.Banerjee, Z.Wang, F.Logna, A.S.Azmi, D.Kong, A.Ahmad, Y.Li, S.Padhye, et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 2012; 72:335-45; PMID:22108826; http://dx.doi.org/10.1158/0008-5472.CAN-11-2182
33. J.Lu, M.L.He, L.Wang, Y.Chen, X.Liu, Q.Dong, Y.C.Chen, Y.Peng, K.T.Yao, H.F.Kung, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011; 71:225-33; PMID:21199804; http://dx.doi.org/10.1158/0008-5472.CAN-10-1850
34. B.Zhang, X.X.Liu, J.R.He, C.X.Zhou, M.Guo, M.He, M.F.Li, G.Q.Chen, Q.Zhao. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 2011; 32:2-9; PMID:20952513; http://dx.doi.org/10.1093/carcin/bgq209
35. X.Dang, A.Ma, L.Yang, H.Hu, B.Zhu, D.Shang, T.Chen, Y.Luo. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet 2012; 205:113-23; PMID:22469510; http://dx.doi.org/10.1016/j.cancergen.2012.01.002
36. J.Kota, R.R.Chivukula, K.A.O'Donnell, E.A.Wentzel, C.L.Montgomery, H.W.Hwang, T.C.Chang, P.Vivekanandan, M.Torbenson, K.R.Clark, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137:1005-17; PMID:19524505; http://dx.doi.org/10.1016/j.cell.2009.04.021
37. X.Yang, L.Liang, X.F.Zhang, H.L.Jia, Y.Qin, X.C.Zhu, X.M.Gao, P.Qiao, Y.Zheng, Y.Y.Sheng, et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology 2013; 58:158-70; PMID:23389848; http://dx.doi.org/10.1002/hep.26305
38. H.R.Ashar, R.A.Chouinard, Jr., M.Dokur, K.Chada. In vivo modulation of HMGA2 expression. Biochim Biophys Acta 2010; 1799:55-61; PMID:20123068; http://dx.doi.org/10.1016/j.bbagrm.2009.11.013
39. O.Li, D.Vasudevan, C.A.Davey, P.Droge. High-level expression of DNA architectural factor HMGA2 and its association with nucleosomes in human embryonic stem cells. Genesis 2006; 44:523-9; PMID:17078040; http://dx.doi.org/10.1002/dvg.20242
40. A.Eda, Y.Tamura, M.Yoshida, H.Hohjoh. Systematic gene regulation involving miRNAs during neuronal differentiation of mouse P19 embryonic carcinoma cell. Biochem Biophys Res Commun 2009; 388:648-53; PMID:19679099; http://dx.doi.org/10.1016/j.bbrc.2009.08.040
41. A.Fusco, M.Fedele. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007; 7:899-910; PMID:18004397; http://dx.doi.org/10.1038/nrc2271
42. V.G.Gorgoulis, P.Zacharatos, G.Mariatos, A.Kotsinas, M.Bouda, D.Kletsas, P.J.Asimacopoulos, N.Agnantis, C.Kittas, A.G.Papavassiliou. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 2002; 198:142-56; PMID:12237873; http://dx.doi.org/10.1002/path.1121
43. B.Eymin, S.Gazzeri, C.Brambilla, E.Brambilla. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001; 20:1678-87; PMID:11313916; http://dx.doi.org/10.1038/sj.onc.1204242
44. D.S.Suh, M.S.Yoon, K.U.Choi, J.Y.Kim. Significance of E2F-1 overexpression in epithelial ovarian cancer. Int J Gynecol Cancer 2008; 18:492-8; PMID:17692085; http://dx.doi.org/10.1111/j.1525-1438.2007.01044.x
45. S.Real, N.Meo-Evoli, L.Espada, A.Tauler. E2F1 regulates cellular growth by mTORC1 signaling. Plos One 2011; 6:e16163; PMID:21283628; http://dx.doi.org/10.1371/journal.pone.0016163
46. G.Hirano, H.Izumi, A.Kidani, Y.Yasuniwa, B.Han, H.Kusaba, K.Akashi, M.Kuwano, K.Kohno. Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells. Mol Cancer Res 2010; 8:864-72; PMID:20530585; http://dx.doi.org/10.1158/1541-7786.MCR-09-0458
47. P.J.Iaquinta, J.A.Lees. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 2007; 19:649-57; PMID:18032011; http://dx.doi.org/10.1016/j.ceb.2007.10.006
48. S.Polager, D.Ginsberg. E2F - at the crossroads of life and death. Trends Cell Biol 2008; 18:528-35; PMID:18805009; http://dx.doi.org/10.1016/j.tcb.2008.08.003
49. J.A.Diehl, M.Cheng, M.F.Roussel, C.J.Sherr. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12:3499-511; PMID:9832503; http://dx.doi.org/10.1101/gad.12.22.3499
50. D.A.Cross, D.R.Alessi, P.Cohen, M.Andjelkovich, B.A.Hemmings. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-9; PMID:8524413; http://dx.doi.org/10.1038/378785a0
51. D.G.Johnson, C.L.Walker. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 1999; 39:295-312; PMID:10331086; http://dx.doi.org/10.1146/annurev.pharmtox.39.1.295
52. B.P.Zhou, Y.Liao, W.Xia, Y.Zou, B.Spohn, M.C.Hung. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001; 3:973-82; PMID:11715018; http://dx.doi.org/10.1038/ncb1101-973
53. M.Fraser, T.Bai, B.K.Tsang. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 2008; 122:534-46; PMID:17918180; http://dx.doi.org/10.1002/ijc.23086
54. N.Bansal, D.C.Marchion, E.Bicaku, Y.Xiong, N.Chen, X.B.Stickles, E.A.Sawah, R.M.Wenham, S.M.Apte, J.Gonzalez-Bosquet, et al. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol 2012; 23:35-42; PMID:22355465; http://dx.doi.org/10.3802/jgo.2012.23.1.35
55. P.Sumazin, X.Yang, H.S.Chiu, W.J.Chung, A.Iyer, D.Llobet-Navas, P.Rajbhandari, M.Bansal, P.Guarnieri, J.Silva, et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 2011; 147:370-81; PMID:22000015; http://dx.doi.org/10.1016/j.cell.2011.09.041
56. G.W.Wright, R.M.Simon. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003; 19:2448-55; PMID:14668230; http://dx.doi.org/10.1093/bioinformatics/btg345
57. R.Clarke, H.W.Ressom, A.Wang, J.Xuan, M.C.Liu, E.A.Gehan, Y.Wang. The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer 2008; 8:37-49; PMID:18097463; http://dx.doi.org/10.1038/nrc2294
58. H.Yang, N.Crawford, L.Lukes, R.Finney, M.Lancaster, K.W.Hunter. Metastasis predictive signature profiles pre-exist in normal tissues. Clin Exp Metastasis 2005; 22:593-603; PMID:16475030; http://dx.doi.org/10.1007/s10585-005-6244-6
59. E.Wingender, X.Chen, R.Hehl, H.Karas, I.Liebich, V.Matys, T.Meinhardt, M.Prüss, I.Reuter, F.Schacherer. TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Res 2000; 28:316-9; PMID:10592259; http://dx.doi.org/10.1093/nar/28.1.316
60. J.Wang, M.Lu, C.Qiu, Q.Cui. TransmiR: a transcription factor-microRNA regulation database. Nucleic Acids Res 2010; 38:D119-22; PMID:19786497; http://dx.doi.org/10.1093/nar/gkp803
61. S.D.Hsu, F.M.Lin, W.Y.Wu, C.Liang, W.C.Huang, W.L.Chan, W.T.Tsai, G.Z.Chen, C.J.Lee, C.M.Chiu, et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res 2011; 39:D163-9; PMID:21071411; http://dx.doi.org/10.1093/nar/gkq1107
62. F.Xiao, Z.Zuo, G.Cai, S.Kang, X.Gao, T.Li. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 2009; 37:D105-10; PMID:18996891; http://dx.doi.org/10.1093/nar/gkn851
63. P.Sethupathy, B.Corda, A.G.Hatzigeorgiou. TarBase: A comprehensive database of experimentally supported animal microRNA targets. RNA 2006; 12:192-7; PMID:16373484; http://dx.doi.org/10.1261/rna.2239606